Menu
Menu
We apply innovative cellular and molecular technologies to study the mechanisms of action, efficacy and safety of pharmaceutical, cosmetic, medical, nanotechnological and food compounds for human health.
One of the objectives of our work is to promote responsible and quality R&D, supporting the European 3R (Replacement, Reduction and Refinement) initiative regarding animal experimentation. To do so, our studies focus on continuous development, improvement and application of in vitro and ex vivo models, different physiological barriers and other systems of interest, such as the skin or the digestive, immune, respiratory and central nervous systems.
Our laboratories are certified as GLP (Good Laboratory Practices) by the Spanish Agency of Medicines and Medical Devices.
We are also members of EU-NETVAL (European Union Network of Laboratories for the Validation of Alternative Methods), REMA (Spanish Network for the Development of Alternative Methods to Animal Experimentation), CTN GET15 – Nanotechnologies Committee, NanoSafety Cluster and the European Technology Platform for Nanomedicine.
The main aim of the project is to develop biomaterials and protocols for administering therapeutic agents so that they can be effectively delivered to both the brain and the lungs. In vitro models of the blood-brain barrier and lung epithelium will be developed to represent the complexity of these systems and facilitate the development of strategies on how to transfer them.
Subsidised by the Basque Government
The aim of the project is to develop a methodology for identifying, assessing and managing risks related to using nanomaterials, so as to prevent potential risks to operators/consumers throughout the life cycle of these types of material.
The RESIST project will evaluate promising new molecules and develop new pharmaceutical nanoformulations and in vitro, in vivo and ex vivo models to help improve and move forward in the fight against antimicrobial resistance (AMR), successfully delivering innovations for a healthier society.
Subsidised by the Basque Government
The main aim of MOSAIC is to carry out bioprospecting aimed at identifying and characterising (i) new microorganisms (fungi and bacteria) with a high capacity to hydrolyse marine polysaccharides, (ii) new families of enzymes (glycosyl hydrolases and sulfatases) with a high potential value for the biomedical and biotechnological industry, and (iii) new active ingredients for the pharmaceutical industry from processing marine glycans.
Subsidised by the Basque Government
The aim of this project is to obtain biocompounds with improved activity for treating cancer by developing new delivery systems, based on nanoencapsulation technologies, which improve the bioavailability of these compounds in oral and topical formulations.
Subsidised by the Basque Government
The main objective of this project is to develop new anti-tumour drugs aimed at inhibiting the mechanisms of blood vessel formation (angiogenesis), stopping tumour growth and inducing the death of malignant cells. This research is aimed at the synthesis, in-vitro evaluation and selection of new molecules with anti-tumour activity against glioblastomas and other tumour types with poor therapeutic efficacy.
Co-funded by the European Regional Development Fund (ERDF)
Development of new imaging techniques and biomaterials for diagnosing diseases of the central nervous system.
Subsidised by the Basque Government
Development of a useful, user-friendly web platform for implementing safe-by-design strategies in companies in the nanotechnology sector. Development of specific modules adapted to the paint industry and 3D printing.
|
| This project received funding from the European Commission's Horizon 2020 research and development programme under contract number 862419. This publication reflects the views of the author only. The European Union is not responsible for any use that may be made of the information contained therein. | ||
Subscribe to our newsletter
